Arcutis Announces Health Canada Approval of Zoryve® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older
Arcutis宣佈其含羅氟米拉斯0.3%泡沫劑(Zoryve®)獲得加拿大衛生部批准,用於治療9歲及以上個體的脂溢性皮炎
Arcutis Announces Health Canada Approval of Zoryve® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older
Arcutis宣佈其含羅氟米拉斯0.3%泡沫劑(Zoryve®)獲得加拿大衛生部批准,用於治療9歲及以上個體的脂溢性皮炎
譯文內容由第三人軟體翻譯。